Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term management--the way forward?

L Wallentin1

  • 1Department of Cardiology, University Hospital, Uppsala, Sweden. lars.wallentin@card.uas.lul.se

Clinical Cardiology
|February 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome.

Journal of internal medicine·2021
Same author

Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial.

Journal of internal medicine·2020
Same author

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.

Journal of internal medicine·2017
Same author

Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.

Journal of internal medicine·2017
Same author

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.

Heart (British Cardiac Society)·2014
Same journal

Strauss-Defined LBBB Identifies Patients With Improved Outcomes After CRT-D: A Comparative Cohort Study.

Clinical cardiology·2026
Same journal

Does Serum γKlotho Truly Provide Incremental Prognostic Value Beyond Established Risk Predictors in Multivessel Coronary Artery Disease?

Clinical cardiology·2026
Same journal

Associations of the C-Reactive Protein-Albumin-Lymphocyte Index, Red Cell Distribution Width-Albumin Ratio, and Blood Urea Nitrogen-Albumin Ratio With All-Cause and Cardiovascular Mortality Among Adults With Preclinical Heart Failure.

Clinical cardiology·2026
Same journal

Real-World National Databases Versus Hypothesis-Driven Cohort Studies: A Reply to the Critique on the TURK-HF Registry Design.

Clinical cardiology·2026
Same journal

Comment on Wang et al.: Unaddressed Multiple Comparisons Risk Inflating Type, Error in Cardiovascular Specialty Nursing Research.

Clinical cardiology·2026
Same journal

Methodological and Statistical Confounding in Comparing Patient-Reported Outcomes Between Cardioversion and Ablation for Atrial Fibrillation.

Clinical cardiology·2026
See all related articles

Low-molecular-weight heparins like dalteparin sodium may extend treatment for unstable coronary artery disease (UCAD). The FRISC II study found dalteparin sodium reduced cardiac events, acting as a bridge to revascularization.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Unstable coronary artery disease (UCAD) treatment typically involves aspirin, unfractionated heparin (UFH), beta blockers, and nitrates.
  • Low-molecular-weight heparins (LMWHs) offer advantages over UFH, prompting investigation into extended treatment durations for UCAD patients.

Purpose of the Study:

  • To evaluate the efficacy of prolonged treatment with the LMWH dalteparin sodium (Fragmin) in patients with UCAD.
  • To assess dalteparin sodium's role as a bridge to revascularization procedures.

Main Methods:

  • The Fragmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) study utilized a factorial design.
  • Patients were randomized to either an invasive or noninvasive management strategy and to dalteparin sodium or placebo treatment.

Related Experiment Videos

Main Results:

  • Dalteparin sodium significantly reduced the incidence of death and/or myocardial infarction (MI) in the initial months.
  • A significant reduction in the triple endpoint (death, MI, revascularization) was observed at 3 months with dalteparin sodium compared to placebo.
  • The risk of new postprocedural events was low in both treatment arms for patients undergoing revascularization.

Conclusions:

  • Dalteparin sodium demonstrates efficacy in reducing cardiac events during the acute phase and serves as a valuable bridge to revascularization in UCAD patients.
  • Prolonged treatment with LMWHs like dalteparin sodium may be appropriate for managing unstable coronary artery disease.